Should Jardiance be Held for 3 Days Before Surgery in Heart Failure or Kidney Disease Patients?
No, you do not need to hold Jardiance (empagliflozin) for 3 days in patients with heart failure or chronic kidney disease—the standard recommendation of omitting it the day before surgery (minimum 36-48 hours) applies to ALL patients regardless of indication, though special attention to heart failure decompensation risk is warranted.
The Evidence-Based Approach
Standard Perioperative Management
The most recent multidisciplinary UK consensus guideline 1 and FDA labeling 2 provide clear but slightly different recommendations:
- Guideline recommendation 1: Omit SGLT2 inhibitors the day before and day of the procedure (minimum 36-52 hours depending on timing)
- FDA recommendation 2: Consider discontinuing at least 3 days prior to scheduled surgery
The guideline approach is more pragmatic and evidence-based. The 2025 consensus statement 1 explicitly notes that previous UK guidelines of omission the day before surgery remain acceptable, and that data suggest omitting the drug >2 days preoperatively did not result in DKA occurring. The risk of perioperative DKA is already low (0.17% for elective surgery) 3, and the 48+ hour window provides adequate drug clearance while minimizing other risks.
Why the Heart Failure/Kidney Disease Indication Doesn't Change the Timeline
The critical nuance: While the FDA label recommends 3 days for scheduled surgery 2, the most recent guideline 1 specifically addresses your concern about heart failure patients. Cessation of SGLT2 inhibitors in patients receiving them for heart failure may be associated with worsening of heart failure. This creates a competing risk:
- Longer cessation = Lower ketoacidosis risk BUT higher risk of:
- Heart failure decompensation
- Perioperative hyperglycemia complications
- Procedure cancellation due to poor glucose control
The guideline explicitly states there needs to be "a balance between stopping the drugs early to prevent the risk of ketoacidosis, against the risks of deferring or cancelling a procedure due to pre-operative hyperglycaemia and risk of postoperative complications" 1.
Practical Algorithm
For Elective Surgery:
Stop Jardiance the day before surgery (minimum timing):
- Morning dose → morning surgery = 48+ hours
- Morning dose → afternoon surgery = 52+ hours
- Evening dose → morning surgery = 36+ hours
Implement ketoacidosis mitigation strategies 1:
- Ensure adequate hydration
- Avoid prolonged fasting periods
- Monitor glucose and ketones
- Consider glucose-containing IV fluids if prolonged fasting unavoidable
Monitor for heart failure decompensation during the withholding period, especially in patients taking Jardiance primarily for heart failure indication
For Emergency Surgery:
The risk of euglycemic DKA is significantly higher (1.1% vs 0.17% for elective) 3 when SGLT2 inhibitors cannot be prophylactically stopped. Heightened vigilance for ketoacidosis is essential regardless of the indication.
Critical Pitfalls to Avoid
Do not assume longer is always safer. Postoperative ketoacidosis has occurred even when patients withheld SGLT2 inhibitors for >72 hours 1, emphasizing that risk exists on a continuum rather than having a defined safe threshold.
Do not forget that euglycemic DKA can occur in patients WITHOUT diabetes 1. The pathophysiology is the same—remain vigilant even in non-diabetic patients taking Jardiance for heart failure or kidney disease.
Do not restart too early. For inpatients, restart only when eating/drinking normally AND capillary ketones <0.6 mmol/L 1. For same-day discharge, restart once eating/drinking normally (usually 24-48 hours post-surgery) 1.
The Bottom Line on the 3-Day Question
The FDA's "at least 3 days" recommendation 2 is conservative and not specifically evidence-based for the timeline. The 2025 multidisciplinary consensus 1—which specifically analyzed the pharmacokinetic/pharmacodynamic profiles and reviewed cases where >2 day cessation showed no DKA benefit—supports the shorter 36-52 hour window as both safe and pragmatic. This applies equally to patients with heart failure or kidney disease, with the added consideration that these patients may actually be harmed by unnecessarily prolonged cessation due to heart failure decompensation risk 1.